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INTRODUCTION
Cholangiocarcinoma is a highly devastating tumor arising
from the epithelial cells of bile ducts. A recent epidemiologic
survey reported that the incidence of cholangiocarcinoma is
increasing in Western countries and the curative therapeutic
approach against this tumor is not available at the present
time (1). Hematologic abnormalities are often found in a vari-
ety of tumorous condition. In particular, thromboembolic
disorders have been reported with an elevated frequency in
cancer patients (2-5). However, few data on this subject are
available in patients with cholangiocarcinoma (2-4). 
We report a case of unexplained pulmonary thromboem-
bolism associated with cholangiocarcinoma, in which coag-
ulation tests showed elevated levels of fibrinogen, fibrinogen
degradation product (FDP), D-dimer, and positive anticar-
diolipin antibody (aCL Ab). 
CASE REPORT
A 56-yr-old man was admitted to our hospital with a com-
plaint of weight loss (6 kg/3 months), and mild shortness of
breath at room air. He denied all past history of smoking,
excessive alcohol drinking, or chronic diseases. On physical
examination, both sclerae were grossly normal, breathing sound
was clear, and no cardiac murmur was heard. Abdominal
sound was normoactive, and organomegaly was not clear.
Arterial blood gas analysis showed pH 7.45, PaO2 65 mmHg,
PaCO2 36 mmHg, and O2 saturation 90%. There was no
evidence of cardiomegaly, mass shadow, or pulmonary edema
in both lung fields on chest radiograph. Laboratory findings
showed alanine aminotransferase of 52 U/L, total bilirubin
of 1.53 mg/dL, alkaline phosphatase of 597 U/L, and  -GTP
of 126 U/L. Hepatitis B virus surface antigen and antibody
to hepatitis C virus were all negative. To evaluate biochemi-
cally abnormal findings, abdominal ultrasonography and
dynamic CT scan were performed, which showed an ill-de-
fined, poorly enhanced 6.5×7×7 cm-sized mass with several
daughter nodules in the left lobe of the liver (Fig. 1). Tests
for tumor markers revealed alfa-fetoprotein of 6.19 ng/mL,
CA 19-9 of 773.2 U/mL, and CEA of 615.5 ng/mL. Ultra-
sonography-guided needle biopsy for the liver mass was per-
formed, and then, the histological findings were compatible
with cholangiocarcinoma (Fig. 2). On chest CT scan for both
of unexplained mild dyspnea and tumor staging, a low den-
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Trousseau’ s Syndrome in Association with Cholangiocarcinoma: 
Positive Tests for Coagulation Factors and Anticardiolipin Antibody
Thromboembolic events are reported to occur with a high frequency in the setting
of malignancy. However, reports on an association between cholangiocarcinoma
and pulmonary thromboembolism, thus far, are almost lacking. We present here
an unusual case of a 56-yr-old patient presenting cholangiocarcinoma and unex-
plained pulmonary thromboembolism. The patient had been quite healthy before
the diagnosis. Coagulation tests showed elevated levels of fibrinogen, fibrinogen
degradation product (FDP), D-dimer, and IgM anticardiolipin antibody (aCL Ab).
The thromboemboli were resolved 3 weeks after anticoagulant therapy using low-
molecular-weight-heparin. Then, follow-up coagulation tests showed a marked
decrease to normal in aCL Ab titer as well as the normalization of FDP and D-dimer
levels. In this case, we describe pulmonary thromboembolism caused by hyperco-
agulable state associated with cholangiocarcinoma and speculate that such a throm-
botic phenomenon could be regressed by anticoagulant therapy. 
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Fig. 1. Abdominal dynamic CT scan show about 6.5×7×7 cm-sized and ill-defined mass with several daughter nodules in the left lobe.
The huge mass with a dilatation of intrahepatic bile ducts is not enhanced on the arterial phase (A), but shows delayed enhancement on
the portal phase (B), indicating cholagiocarcinoma.
A B
Fig. 2. Photomicrograph of liver biopsy specimens. Moderately differentiated adenocarcinoma is shown in the hematoxylin-eosin stain (A;
original magnification ×100). On the immunohistochemical staining by using cytokeratin 19 (CK 19), dark-brown staining patterns are
observed on the epithelium of proliferating bile ducts (B; original magnification ×400).
A B
Fig. 3. Initial chest CT scan shows (A) a filling defect with lower density in the left interlobar pulmonary artery, indicating pulmonary thrombo-
embolism. (B) Follow-up chest CT scan after anticoagulant therapy over 3 weeks revealed the interval regression of the thromboembolism.
A
Bsity due to filling defect in the left interlobar pulmonary artery
was found without any evidence of other metastatic nodules
(Fig. 3A). Pulmonary perfusion scan showed multiple per-
fusion defects in the left lower lung fields (Fig. 4). Echocar-
diographic examination revealed no evidence of vegetation
on the cardiac valves or intracardiac thrombus. Based on the
radiological and symptomatic findings of the patient, the
diagnosis of pulmonary thromboembolism was made. At the
time of diagnosis, coagulation tests showed elevated levels
of blood clotting factors, such as D-dimer of 5,690 ng/mL,
fibrinogen of 746 mg/dL, fibrinogen degradation product
(FDP) of 8.02  g/mL, and positive IgM anticardiolipin anti-
body (aCL Ab) of 73 PL (normal limit: <20 PL). The pro-
thrombin time (PT) was 10.8 sec (international neutraliza-
tion ratio [INR]=0.98), activated partial prothrombin time
(aPTT) was 33.2 sec, and other coagulation factors including
protein C and S activities, lupus anticoagulant and antithrom-
bin III are all within the normal range. To treat the pulmo-
nary thromboemboli, anticoagulation therapy using low-
molecular-weight-heparin (LMWH) in therapeutic dose of
10 IU/kg every 12 hr was given subcutaneously. The patient’s
symptom was relieved with LMWH treatment over time
and the follow up CT scan at 3 weeks after the diagnosis
showed an almost complete resolution of the thromboemboli
(Fig. 3B). Blood oxygenation was also increased to PaO2 of
83 mmHg and O2 saturation of 97%. Follow-up coagulation
tests demonstrated the normalization of FDP, D-dimer, and
IgM aCL Ab titer, but only a slight decrease in fibrinogen
level (Fig. 5). Systemic chemotherapy for the cholangiocar-
cinoma was performed. The patient has been followed up
without further thrombosis during the next 3 months. 
DISCUSSION
In 1865, Trousseau first described the relationship between
neoplastic and thromboembolic disease (6). Since then, a vari-
ety of thromboembolic events including spontaneous, recur-
rent, or migratory vascular thrombosis, microangiopathy,
acute bleeding diathesis, and disseminated intravascular coag-
ulation in cancer patients have been termed Trousseau’s syn-
drome (5, 7). It also presents as non-bacterial thrombotic
endocarditis (NBTE), deep vein thrombosis, pulmonary/me-
senteric thrombosis, and stroke (2-9). The prevalence of the
syndrome was reported to be from 1% to 11% (9, 10). Under
the conditions, clinical manifestation of blood coagulopathies
ranges from subclinical status to full-blown massive throm-
boembolisms causing a fatality (11). This syndrome often
precedes the initial manifestation of malignancy (8), so that
unexplained thromboembolic events occasionally provide a
clue to diagnosis of occult malignancy (9).
Our case has a pulmonary thromboembolism associated
with cholangiocarcinoma. To our knowledge, there has been
only one case reported on the association of cholangiocarci-
noma with pulmonary thromboembolism (2). There was no
evidence of immobilization, surgery, or trauma, which are
known as risk factors for pulmonary thromboembolism or
deep vein thrombosis. Concerning the pulmonary emboli in
this case, the question of whether the emboli came from the
malignant cells or were induced via blood hypercoagulability
could be raised. However, the follow-up chest CT showed
an almost complete resolution of the thromboemboli by anti-
coagulant using LMWH. This finding, thus, suggests that
the pulmonary emboli was not caused by malignant cell clus-
ter but caused by blood hypercoagulability. 
NBTE, as a manifestation of Trousseau’s syndrome, has
been reported in up to 1.3% of patients dying of cancer (12).
Cerebral arteries are most commonly involved sites (4). In
our case, no evidence of vegetations was seen on echocardio-
graphy, and the patient had no neurologic abnormalities.
However, the possibility of NBTE should be considered in
all cancer patients presenting with acute stroke syndrome,
since it is responsible for around one-third of cerebral infarc-
tions and the diagnosis can be often difficult to establish ante-
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Fig. 4. Ventilation-perfusion scan reveals that no definite ventilatory
abnormality in both lungs is shown (A), but multiple perfusion
defects are found on the left lower lobe (B). 
Fig. 5. Changes in FDP, D-dimer, fibrinogen, and aCL Ab levels
during anticoagulant therapy. The levels of FDP, D-dimer, and aCL
Ab were normalized, but fibrinogen level was slightly decreased.
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mortem (4). Apart from NBTE, the possibility of antiphos-
pholipid syndrome (APS) may also be raised, given the posi-
tive test for aCL Ab in our case. APS is suspected by the occur-
rence of one or more thromboembolic events, pregnancy loss,
or premature births in the presence of antiphospholipid anti-
bodies (aPL Ab). Of note, the syndrome is excluded if there
is associated infection, cancer, and the use of drug known to
induce aPL Ab (13). Thereby, the sole diagnosis of APS is
less likely in the present case.
The full mechanism of cancer-induced coagulopathy has
not yet been clarified. Recently, possible hypotheses explain-
ing this phenomenon have been proposed (11, 14). Growing
tumor leads to tissue hypoxia, and then, tumor cells in turn
produce procoagulant and angiogenic factors. Tumor cells
can also interact with host cells and vascular endothelium,
causing endothelial cell injury. In addition, host blood cells
and smooth muscle cells secrete procoagulant factors. More-
over, the coagulation and fibrinolytic activities are dysregu-
lated as well. These tumor cell- and host cell-induced, dys-
regulated coagulation and fibrinolysis are considered to pro-
vide a synergistic means of inducing a cancer-related hyper-
coagulable state (11, 14).
D-dimer and FDP levels are significantly elevated in patients
with deep venous thrombosis, pulmonary embolism, and
disseminated intravascular coagulation (15, 16). Serial mon-
itoring of those levels is reported to be of value in evaluating
the response to treatment, and persistently positive levels
suggest a higher risk of recurrent episodes of thromboem-
bolism (15, 16). In our patient, highly elevated levels of D-
dimer and FDP at baseline were improved and significantly
reduced following anticoagulant therapy, suggesting that the
patient achieved a good response to anticoagulant therapy.
Interestingly, aCL Ab titer was also normalized together with
a resolution of the pulmonary thromboembolism following
anticoagulant therapy. Although an association between the
presence of aCL Ab and thromboembolic events in healthy
populations is still debated (17), previous reports consistently
demonstrated an positive correlation between the two in the
setting of malignancy (18-20). Among the coagulation fac-
tors examined, aCL Ab was more likely to be clinically cor-
related with thrombotic process in our patient, suggesting
that it might play a role in the development of the throm-
boemboli. Taken together, under the cancer-induced hyper-
coagulable state as reflected in the elevated levels of fibrino-
gen, FDP, and D-dimer, aCL Ab might have triggered or
enhanced, at least in part, the thrombosis in our case. 
For patients with Trousseau’s syndrome, therapy targeted
for the underlying malignancy may be reasonable. It is because
as long as tumor persists, thrombotic process will be ongo-
ing (9). For this complication, anticoagulant is needed as a
prophylaxis and treatment. A recent experimental study
demonstrated the advantage of LMWH over unfractionated
heparin for cancer-related thromboembolism (21). Consis-
tently, LMWH is also reported to have a therapeutic benefit
in clinical applications (9, 22). We chose LMWH as the first-
line anticoagulant for the thromboemboli and the present
case supported the efficacy of LMWH. Despite the relatively
short-term follow-up interval of 3 weeks, the pulmonary
thromboembolism was successfully treated by LMWH and
never recurred during the next 3 months.
In conclusion, we herein report an unusual case of Trousseau’s
syndrome associated with cholangiocarcinoma and pulmonary
thromboembolism. This is a case of Trousseau’s syndrome
with cholangiocarcinoma supported by clinical evidence of
abnormally increased blood clotting factors, such as fibrino-
gen, FDP, D-dimer, and aCL Ab. Although the precise mech-
anisms have not yet been confirmed, this case highlights the
implication that procoagulant factors or aPL Ab may play
an important role in the thrombotic process in cancer patients,
and anticoagulant therapy with LMWH may be helpful to
relieve thrombotic symptoms.
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